Wednesday, April 16, 2014

Non-Small Cell Lung Cancer - References

References


  • U.S. Food and Drugs Administration. Alert for Healthcare Professionals: Iressa (gefitinib).
  • Fehrenbacher L. A Phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory NSCLC. Proceedings from the 42nd Annual Meeting of the American Society for Clinical Oncology. Atlanta, GA. June 2006.
  • San JosĂ© S, Arnaiz MD, Lucas A, et al. Radiation therapy Alone in Elderly with Early Stage Non-Small Cell Lung Cancer. Lung Cancer. 2006;52:149-54.
  • National Center for Health Statistics. Lung and Bronchus Cancer: U.S. Death Rates† By Sex and Race/Ethnicity 1992-2002 (table).
  • U.S. National Institutes of Health. National Cancer Institute. Non-Small Cell Lung Cancer: Treatment: General Information. In: Physician Data Query.
  • U.S. National Institutes of Health. National Cancer Institute. Non-Small Cell Lung Cancer: Treatment: Cellular Classification. In: Physician Data Query.
  • U.S. National Institutes of Health. National Cancer Institute. Non-Small Cell Lung Cancer: Treatment: Cellular Classification. In: Physician Data Query.
  • Merck & Co. http://www.Vioxx.com. Last Accessed on June 22, 2006. U.S. Food and Drug Administration. COX-2 Selective (includes Bextra, Celebrex, and Vioxx) and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Available at: http://www.fda.gov/cder/drug/infopage/COX2/default.htm. Last Accessed on June 22, 2006.


Review Date: 06/30/2006
Reviewed By: Harvey Simon, MD, Editor-in-Chief, Associate Professor of Medicine, Harvard Medical School; Physician, Massachusetts General Hospital.

A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org)